$SLN 8-K/A SEC Filings

Filed On	Filing
16 Jul 2026	8-K/A: Departure/Election of Directors or Officers; Compensation As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).
22 Dec 2025	8-K/A: Departure/Election of Directors or Officers; Compensation Update Regarding Principal Executive Officer Compensation Arrangement